|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<i>Fn</i> DNA in the tumor tissue was significantly associated with proximal tumors (<i>p</i> = 0.001), higher depth of invasion (<i>p</i> = 0.014), higher clinical stages (<i>p</i> = 0.033), poor differentiation (<i>p</i> = 0.011), MSI-positive status (<i>p</i> < 0.0001), BRAF mutated tumors (<i>p</i> < 0.0001), and the loss of expression of mismatch-repair proteins MLH1 (<i>p</i> < 0.0001), MSH2 (<i>p</i> = 0.003), and PMS2 (<i>p</i> < 0.0001).
|
31555583 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF (Raf kinase type B) mutant carriers showed increased risk of developing invasion compared with wild-type (WT) cases.
|
21389096 |
2011 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF(V600E) mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis.
|
22767446 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF mutation examined in FNAB specimens, compared with the wild-type allele, strongly predicted perithyroidal invasion (48 vs. 29%; P = 0.017), extracapsular spread (65 vs. 45%; P = 0.017), occult central lymph node metastasis (35 vs. 15%; P = 0.004), and advanced TNM stage (44 vs. 28%; P = 0.035).
|
22930785 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF (V600E) causes upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which promotes cell invasion in papillary thyroid carcinoma (PTC).
|
23893334 |
2013 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
BRAF is a key component of mitogen-activated kinase pathway; its activating mutation leads to accelerated melanoma cells proliferation, invasion and survival.
|
25888143 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BRAF-positive malignancies were more likely to demonstrate extrathyroidal extension (P = .003), lymphovascular invasion (P = .02), and lymph node metastasis (P < .001).
|
27689252 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A high BRAF mutation rate was associated with female, poor differentiation, lymphovascular invasion and positive tumor deposits.
|
31162857 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Additional genotyping of PTC cases for the BRAFV600E mutation revealed for the first time a close relation between SLP-2 overexpression and the presence of BRAF mutation (p = 0.02) with high positive rates of lymph node metastasis (70%) and extrathyroid invasion (80%) in these cases.
|
26750533 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells.
|
15761501 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Based on MSI, and CIN, 3 classes were defined: (i) High microsatellite instability MSI-H tumors: young age, high carcinoembryonic antigen (CEA) level, right colon, poorly differentiated, mucin production, high BRAF mutation, lower allelic loss and relatively good prognosis; (ii) Microsatellite stability (MSS) diploid tumors: right colon, poorly differentiated, less infiltrative tumor, mucin production, lower allelic loss and low p53, BRAF mutation; (iii) MSS aneuploid tumors: more infiltrative invasion, greater allelic loss and high p53 mutation.
|
16231316 |
2006 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By contrast, positive status of BRAF(V600E) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18).
|
26871894 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019).
|
28004221 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Chitosan nanoparticle-mediated BRAF siRNA interference evidently reduced the invasion capacity of gastric cancers.
|
25794798 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Coexistence of BRAF V600E and TERT promoter mutations was particularly associated with high-risk clinicopathological features, as exemplified by extrathyroidal invasion seen in 54.5% (12/22) of patients harboring both mutations versus 9.9% (23/232) of patients harboring neither mutation (P < 0.001).
|
26943032 |
2016 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Compared with BRAF wild-type adenocarcinomas, BRAF-mutated adenocarcinomas more frequently demonstrated adverse histologic features such as lymphatic invasion (16/20, 80% vs. 75/161, 47%; P=0.008), mean number of lymph node metastases (4.5 vs. 2.2; P=0.01), perineural invasion (8/20, 40% vs. 13/161, 8%; P=0.0004), and high tumor budding (16/20, 80% vs. 83/161, 52%; P=0.02).
|
22314188 |
2012 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Concerning the prognostic role of BRAF mutation for the two categories, we reported a significant correlation with multifocality, nodal involvement and extra-capsular invasion (P<0.0001).
|
23513230 |
2013 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Deletions on chr 10q11.21-26.2, a region harboring the tumor suppressor genes, PDCD4, SUFU, NEURL1, PTEN, RASSF4, DMBT1, and C10orf90 and C10orf99, significantly correlated with metastasis (Fisher's exact, p ≤ 0.04), lymphatic invasion (Fisher's exact, p ≤ 0.02), increasing tumor thickness (Mann-Whitney, p ≤ 0.02), and BRAF mutation (Fisher's exact, p ≤ 0.05).
|
30672666 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells.
|
29085476 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Doxycyclin-inducible knockdown of endogenous B-Raf(V600E) decreases cellular motility and invasion in conventional and three-dimensional (3D) culture, whereas it promotes cell-cell contacts and induces various hallmarks of differentiated epithelia.
|
25381152 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Dual inhibition of BRAF(V600E) and MEK reduced but did not prevent SW1736 invasion although rebound phosphorylation of ERK in response to PLX4720 was blocked by U0126.
|
26384551 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Except for age, BRAF(+) and BRAF(-) did not differ in sex, tumor size, histological subtype, multifocality, vascular invasion, extrathyroidal extension, or prognostic staging.
|
24468978 |
2014 |